Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies

Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies

US Patent 10647706 · Granted May 12, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors2023
MTOR inhibitor compounds2022
Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan 2020
Benzimidazole sulfonamide derivatives as inverse agonists of retinoid-related or2020
Benzenesulfonamide compounds, method for synthesizing same, and use thereof in m2020
Tetrahydroquinoline sulfonamide derivatives as inverse agonists of retinoid-rela2020
Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan re2019
Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the 2019
Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the 2019
Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan 2019
Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same a2017
Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treat2017